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A B S T R A C T
Although status epilepticus (SE) affects the course of Dravet syndrome (DS), it rarely alters dramatically
psychomotor outcome. We report an unusual pattern in 3 patients who following refractory SE lasting
respectively 2, 7 and 12 h experienced persistent and severe cognitive and motor deterioration. We
compared these patients to published data and to personal experience in Necker hospital, to ﬁnd links
between severe outcome and clinical features such as treatment or duration of refractory SE. The key
point was that anoxoischemic-like lesions appeared on MRI although cardiovascular function had
remained stable. Therefore, neither hemodynamic failure, nor abnormalities of cardiac rhythm could
explain the lesions and neurological worsening. For theoretical reasons the responsibility of therapy
common for the 3 patients, e.g., barbiturates was suspected.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Dravet syndrome (DS) is characterised by prolonged, often
unilateral seizures triggered by fever in infants with previously
normal psychomotor development, delayed occurrence of myoc-
lonus and later various seizure types with psychomotor retarda-
tion. EEG andMRI show no speciﬁc pattern. High seizure frequency
during the ﬁrst 2 years is correlated with a worse cognitive
outcome.1 Prolonged seizures are frequent during the ﬁrst three
years of life, but they rarely last more than 2 h and are usually
followed by recovery of the previous condition. They occurred in
about 70% of the children.1,2 Severe deterioration following SE is
not usual.2 We report 3 patients with severe neurological
regression following SE, and compared them to reported data in
order to consider risk factors for this severe event.
Patients and methods
Among the 103 patients followed for DS in our hospital, 92%
experienced at least one SE. For the 70% of patients with available* Corresponding author at: Service de neurope´diatrie, Centre de re´fe´rence
e´pilepsies rares, AP-HP, Hoˆpital Necker Enfants Malades, Paris, France.
Tel.: +33 144481536; fax: +33 142192692.
E-mail address: mathilde.chipaux@nck.aphp.fr (M. Chipaux).
1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.01.007data regarding duration of status and drugs administered, SE lasted
from 30 min to 8 h with recovery of the previous condition in most
instances.
We, however, encountered 3 childrenwith severe cognitive and
motor deterioration following refractory SE (Table 1). None of the 3
patients presented a personal history and a familial history of
febrile seizures was reported for patient 2. Molecular genetics
showed SCN1A mutation in all 3. We analyzed their clinical
characteristics, and family and personal histories. We also
reviewed brain imaging and EEG recordings to identify risk factors
for such poor motor and cognitive outcome.
Results
The 3 children had experienced 4 to 7 episodes of SE between 7
and 36 months of age. Cognitive development was as expected in
DS. The ﬁrst child had undergone psychomotor evaluation (Brunet-
Lezine scale) at 9 months, with a score of 83, normal speech and
lack of behavioural impairment, before the severe status occurred
at 13 months. The second child had just begun to walk alone and
communication was considered normal for the age, when the
severe SE occurred at 16months. The third patient hadmildmental
retardation at age 36 months when severe SE occurred, but no
cognitive scale was performed as the diagnosis of DS had not yet
been suspected. Severe status consisted of continuous, bilateral
clonic movements with loss of consciousness lasting respectivelyvier Ltd. All rights reserved.
Table 1
Demographic characteristics of the 3 patients.
Patients D. L H. C M. V
Birth date 09/05/2006 12/09/2003 04/15/1997
Family history No Febrile seizures No
Personal history No No No
Mutation C5341T>C p.Ser1328Pro C4720delT
Age at ﬁrst seizure 2 months 6 months 9 months
Number of previous SE 4 5 7
Duration of previous SE 30–60mn 30–60mn 30mn–2h30
Age at ﬁrst SE 6 months 6 months 12 months
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rate, oxymetry and blood pressurewere continuouslymonitored in
the intensive care unit and remained normal. No abnormality of
glycemia or natremia was noticed.
Clinical characteristics of SE, monitoring and treatment are
given in Table 2. The ﬁrst patient received a combination of
benzodiazepines and phenytoin followed by phenobarbital. The
second received thiopental responsible for suppression-bursts
patterns on his EEG, after benzodiazepines, phenytoin andTable 3
Outcome.
Clinical data after SE Hypotonia, dystonia Hypo
Cognitive data Standing with help, voluntary grasping No e
Speech 2–3 words No
Age of 1st MRI 3 months 5 mo
1st MRI ﬁndings Normal Norm
Age of last MRI 13 months 18 m
Last MRI ﬁndings Cortical and sub-cortical atrophy,
with reduced white matter
Corti
with
Table 2
Features of the complicated SE.
Age at complicated SE (CSE) 13 months 16 months
Duration of CSE 12h 7h
Hemodynamic failure No No
Cardio-pulmonary and
oxymetry monitoring
Normal Normal
Drugs given chronically Valproate 30mg/kg/d Stiripentol
2 months b
Valproate 2
Clobazam 2mg/kg/d
Stiripentol 75mg/kg/d
Clobazam 1
Drugs used for the
previous status
6.5 months: (<1h)
Diazepam 2mg/kg
Phenytoin 15mg/kg
7.5 months: (<1h)
Diazepam 2 mg/kg
Phenobarbital 15 mg/kg
(4 status <1
Diazepam
for status
Diazepam, C
Phenobarbi
status 3 and
7.5 months: (<1h)
Diazepam 2 mg/kg
Phenobarbital 15 mg/kg
Drugs used for the CSE Diazepam 2mg/Kg, Diazepam 1
Phenobarbital 20mg/kg, Phenobarbi
Phenytoin 15mg/kg,
Clonazepam 0.3mg/kg
then 1.2mg/kg/d
Midazolam
(1 dose), Ph
Pentothal 4phenobarbital. The third was treated with high doses of
phenobarbital after benzodiazepines. Before this SE, the 3 children
had a combination of valproate and clobazam for the 2 ﬁrst
patients, clonazepam for the third one. Stiripentolwas added to the
AEDs in patients 1 and 2, during the 2 months preceding the
refractory SE; The third one did not receive stiripentol.
Following status epilepticus, all three patients experienced
massive neurological regression, becoming hypotonic with spastic
tetraplegia and loss of eye contact (Table 3). Six months after the
status, at 19 months, the ﬁrst child had moderately improved but
remained hypotonic and could not walk; he said only 2–3 words
and suffered from dystonia mainly in the face. Patients 2 and 3 had
not recovered previous state several years later: both exhibited
major hypotoniawith poor eye contact, had totally lost speech, and
remained dependent for feeding. Both had spastic tetraplegia, one
had dystonia.
All 3 patients had previously normal brain MRI, conﬁrmed on
retrospective examination (Fig. 1). A secondMRIwas performed 3–
8 weeks after the prolonged SE showed in all 3 patients major
cortical and white matter but only slight atrophy of basal ganglia
(Figs. 1 and 2). Perfusion CT scan performed for patient 1 two
weeks after the status showed 30% reduction of cerebral blood ﬂowtonia, spastic tetraplegia Hypotonia, dystonia, spastic tetraplegia
nvironmental interaction Eye contact only
No
nths 29 months
al Normal
onths 39 months
cal and sub-cortical atrophy,
diffuse anoxoischemic lesions
Cortical and sub-cortical atrophy,
anoxoischemic lesions.
38 months
2h
No
Normal
62mg/kg/d, started
efore
1mg/kg/d
Valproate 40mg/kg/d
Clonazepam 1mg/kg/d
.4mg/kg/d
h)
and Clonazepam
1 and 2
lonazepam and
tal 15 mg/kg for
4
10 months: (1h30)
Diazepam 0.5mg/kg
Valproate 12mg/kg
Clonazepam 0.4mg/kg/d
Phenobarbital 15mg/kg
Phenytoin 15mg/kg/d
Fluid resuscitation and
Dopamine 5mg/kg/d
30 months: (2h30)
Diazepam 1.4mg/kg
Clonazepam 0.03/kgmg and 0.02mg/kg/h
Phenobarbital 20mg/kg
4 others: (<1h)
Diazepam then clonazepam
mg/Kg Diazepam 1mg/kg
tal 10mg/kg Midazolam 0.3mg/kg in 2 doses
(1 dose), Clonazepam
enytoine (1 dose)
mg/kg, single dose
Phenobarbital 15mg/kg then 1mg/kg/h
Fig. 1. MRI of patient 1 before (age 3 months) (a) and 2 months after complicated SE (age 13 months) (b).
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the same age.
Discussion
Clinical characteristics of our 3 patients were initially typical
for DS, but their evolution was unusual: sudden and severe
worsening followed prolonged and drug resistant SE. Two of them
hadno improvement after several years of followup, and although
patient 1 slightly improved, she did not recover previous
condition. Although Oguni et al. published 2 children with
‘‘residual severe neurological deﬁcits after prolonged SE’’, this
post-ictal deterioration is unusual in DS.2 In our series, this
deterioration encouraged search of an alternative diagnosis but
molecular ﬁndings conﬁrmed the diagnosis of DS and avoided
useless further investigations.
The high frequency of uni- or bilateral SE triggered by fever in
DS contrasts with the usual lack of lasting post-ictal motor deﬁcit,
and the severity of DS is mainly related to mental delay, not to
gross motor defect.1–3 Despite post-ictal motor defect, patients
usually recover within a few hours. The three reported patients
contrast by severe persistent neurological deterioration following
prolonged SE. The combination of pyramidal and extrapyramidal
signs is reminiscent of systemic hemodynamic failure, causing
lesions in white matter and basal ganglia, as seen in ischemic
encephalopathy (Fig. 2). Such cerebral abnormalities are distinct
from those reported in DS. Early MRI of patients with DS, usually
performed within the ﬁrst 2 year of life, is normal.1 Later in life,
temporal sclerosis is occasionally reported, as well as non-speciﬁcatrophy.2,4,5 Other reports mention atrophy and white matter T2
hyperintensities.3,5 Diffuse cortico-sub-cortical atrophy with
abnormal white matter signals has not been reported.
Three hypotheses may account for such deterioration: hemo-
dynamic failure due to long duration of SE, cardiac rhythm
abnormalities related to DS channelopathy, and reduced local
cerebral blood ﬂow related to drugs administered for SE.
Although following prolonged SE cognitive and behavioural
troubles affect 20–79% of patients, motor troubles are usually
mild.6 Whether mortality or morbidity increases with the
duration of SE remains unclear.7 Patient 3 had previously
suffered from prolonged seizures without similar consequences,
as 92% of DS children followed in our institution. Age and
duration of SE could be risk factor since most previous episodes
of SE in these patients had occurred in the ﬁrst year of life and
had lasted for less than 1 h. However, for patient 3, a very
similar episode had occurred in the same age range (30 months)
and had lasted the same time (2.5 h) without such a dramatic
outcome.
Energy needs of brain cells increase during seizures and blood
ﬂow increases by 2–3 folds (SPECT or PET), especially for long
lasting seizures.8 Prolonged seizures cause neuronal death due to
necrosis or apoptosis, following oedema and blood-brain barrier
lesions.9 Anoxo-ischemic lesions could result from insufﬁcient
perfusion of discharging cells. However, systemic hemodynamic
failure was not noticed for any of the 3 patients in intensive care
unit.
Acute anoxo-ischemia could result from cardiac arrhythmia,
possibly linked to sodium channel abnormalities of DS. This could
Fig. 2.MRI of patients 2 and 3 after complicated SE (a, b) on T2 weighted sequence compared to normal (c) and acute anoxic-ischemia at the same age (d). MRIs (a, b) were
performed at mean 6 weeks after the event. The MRI of patients with DS (a, b) shared severe cortical atrophy similar to that of postanoxic-ischemic lesions but in addition
dramatic loss of white matter with slight basal ganglia atrophy.
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account for the higher incidence of sudden death in patients with
DS.10,11 In Dravet’s series, two out of 63 children died suddenly3
and 2 out of 41 in Chiron et al’s series.12 Our patients were,
however, in ICU and no change of cardiac rhythms was identiﬁed
despite continuous monitoring.
Brain damage could result from the medications adminis-
tered: barbiturates and phenytoin. Phenytoin can produce
cardiac dysrhythmia, but the compound was administered in
the ICU without any impact on ECG monitoring. Barbiturates or
its combination with stiripentol could have reduced local
cerebral blood ﬂow. Wada et al. showed that high doses of
barbiturates decrease cerebral blood ﬂow by over 25% (p < 0.01)
during 3 h following the administration in animals.13 This was
conﬁrmed in humans by transcranial Doppler measures.14 When
thiopental is used in paediatric SE, the mortality rate seems to
be raised, compared with propofol.15 Thiopental use in adult
refractory SE has some rational because the mortality rate is 10
fold higher than in children.6,16 Moreover, stiripentol inhibits
P450 cytochrome metabolism, so blood levels of barbiturates
could have been increased in the patients 1 and 2, especially
following repeat barbiturate injections. Unfortunately, no blood
levels were available. Patient 2 received one high dose of
pentothal; patient 3 received a continuous high dose adminis-tration of phenobarbital. No published data compare the effects
of different antiepileptic schedules for SE in patients with DS. In
our retrospective series, data were missing for 30% of the DS
patients, and for the remaining 70%, no blood levels were
available. Unfortunately, for the 2 patients reported by Oguni
et al. with residual severe neurological deﬁcits after prolonged
SE, no data is given regarding the treatment used for the SE.2
Conclusion
Refractory SE may dramatically alter neurological outcome in
DS. SE is frequent in this disease but rarely causes anoxo-
ischemic lesions. There are theoretical reasons to suspect that
barbiturates in DS could contribute to such brain damage. It
seems reasonable to suggest avoiding thiopental in SE occurring
in patients with DS and restraining the administration of
barbiturates to failure of alternative possibilities, with strict
monitoring of AEDs blood levels, especially for patients who
receive polytherapy including compound that reduce barbitu-
rate clearance.
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